MOLN News and Press, Molecular Partners AG From 05/24/24

Toto Ltd ADR (TOTDY) is expected to report for Q4 2024 NSK Ltd. ADR (NPSKY) is expected to report for Q4 2024 Monarch Cement Co. (MCEM) is expected to report for Q1 2024 HST Global Inc (HSTC) is expected to report for Q1 2024 Sumitomo Heavy Industries Ltd. ADR (SOHVY) is expected ...

Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...

MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being prepared Radio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano ...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells Results highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic advers...

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geograph...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions propos...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the A...

2024-03-15 11:20:08 ET Molecular Partners AG (MOLN) Q4 2023 Earnings Conference Call March 15, 2024 08:00 AM ET Company Participants Seth Lewis - SVP, IR Patrick Amstutz - CEO Robert Hendriks - SVP, Finance Philippe Legenne - Acting Chief Medical Officer ...

2024-03-14 16:21:05 ET More on Molecular Partners Molecular Partners AG 2024 Q2 - Results - Earnings Call Presentation Molecular Partners says data from projected therapeutically active doses of MP0533 from Phase 1/2a trial to be presented in H1 Molecular Partners, O...